Trevi Therapeutics (TRVI) saw its stock climb 4.5% following Stifel's bullish price target revision, reflecting growing confidence in the company's lead drug candidate Haduvio and its potential in treating chronic cough conditions.
The investment bank's decision to raise its price target by 50% stems from optimistic predictions regarding upcoming trial data for Haduvio in refractory chronic cough (RCC). Stifel analysts particularly emphasized the drug's demonstrated efficacy in treating idiopathic pulmonary fibrosis-related chronic cough, a notably challenging condition that has shown resistance to existing therapeutic options.
Clinical Development Progress
The company's development program reached a significant milestone in December when it confirmed no modifications would be necessary for the sample size of its ongoing Phase 2b study of Haduvio in chronic cough patients with idiopathic pulmonary fibrosis. This development maintains the study's timeline, with topline data expected in the first half of 2025.
Market Potential and Therapeutic Applications
Stifel's analysis suggests broader applications for Haduvio beyond its current target indications. The drug's potential effectiveness in RCC could pave the way for its use in treating various forms of moderate-to-severe coughs, significantly expanding its therapeutic reach and market potential.
Market Performance
The market has responded positively to Trevi's development progress, with the company's shares demonstrating strong momentum. Over the past three months, TRVI stock has surged 75%, including a 19% increase in the last month alone, reflecting growing investor confidence in the company's clinical programs and market potential.
Therapeutic Mechanism
Haduvio's unique position as a mixed opioid drug offers a novel approach to treating chronic cough conditions. Its mechanism of action appears particularly effective in addressing IPF-CC, where other therapeutic interventions have fallen short, potentially representing a significant advancement in treatment options for patients with limited alternatives.
